|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����Ǵ�,ϵͳ�� |
|
��ͯ |
|
���� |
| ��������������� | |
|
����Ƽ |
|
����� |
|
��ɭ |
|
��ѧ�� |
| PubMed | |
|
Article by CHEN Qiu-ping |
|
Article by WANG Pei-guang |
|
Article by YANG Sen |
|
Article by ZHANG Xue-jun |
��ͯϵͳ�Ժ���Ǵ��Ľ�չ
����Ƽ, �����, ��ɭ, ��ѧ��
����ҽ�ƴ�ѧ��һ����ҽԺƤ���Բ���, 230022
��ͯϵͳ�Ժ���Ǵ������Ŵ����������Լ��صȶ����ع�ͬ��������Ķ�ϵͳ���۵����������Լ�������������,��ͯϵͳ�Ժ���Ǵ�����������,���̽�չ��Ѹ�١������Ƹ��ݲ���������������۳̶ȶ���,����Ƥ�ʼ��غ��������Ƽ�Ϊ����������������Ч��ֹ����������˥�ߵķ������Ի����������Ƶֿ�������Զ�ͯϵͳ�Ժ���Ǵ����û����ء�����������������������
Some clinical advances in pediatric systemic lupus erythematosus
Institute of Dermatology, First Affiliated of Anhui Medical University, Hefei 230022, China
Institute of Dermatology, First Affiliated of Anhui Medical University, Hefei 230022, China
Pediatric systemic lupus erythematosus (pSLE) is a multi-system autoimmune disease caused by the interplay of environmental, sex hormonal and genetic factors. In general, pSLE tend to have an earlier involvement of organ and more aggressive clinical course compared with adult SLE. The treatment of pSLE varies with the disease severity and organ involvement degree. Corticosteroids and immuno-suppressants are the primary choices for pSLE therapy. Cyclophosphamide (CTX) can effeciently prevent the occurrence of chronic renal failure. Cyclosporine A, mizoribine and rituxima are recommended for CTX-resisting pSLE patients.
[2] Klein-Gitelman M,Reeiff A,Silverman ED.Systemic lupus erythe matosus in childhood.Rheum Dis Clim North Am,2002,28(3):561-577,vi-vii.
[3] Guevara JP,Clark BJ,Athreya BH.Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus.J Rheumatol,2001,28(4):854-859.
[4] Arkachaisri T,Lehman TJ.Systemic lupus erythematosus and related disorders of childhood.Curr Opin Rheumatol,1999,11(5):384-392.
[5] Trapani S,Camiciottoli G,Ermini M,et al Pulmonary involvement in juvenile systemic lupus erythematosus:a study on lung function in patients asymptomatic for respiratory disease.Lupus,1998,7(8):545-550.
[6] Bogdanovic R,Nikolic V,Pasic S,et al.Lupus nephritis in childhood:a review Of 53 patients followed at a single center.Pediatr Nephrol,2004,19(1):36-44.
[7] Bakkaloglu A.Lupus nephropathy in children.Nephrol Dial Transplant,2001,16(Suppl 6):126-128.
[8] Zappitelli M,Duffy C,Bernard C,et al.Clinicopathological study of the WH0 classification in childhood lupus nephritis.Pediatr Nephrol,2004,19(5):503-510.
[9] Schmugge M,Revel-Vilk S,Hiraki L,et al.Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus.J Pediatr,2003,143(5):666-669.
[10] Tseng CE,Buyon JP,Kim M,et al.The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active,but clinically stable,systemic lupus erythematosus:findings of a prospective,randomized,double-blind,placebo-controlled trial.Arthritis Rheum,2006,54(11):3378-3380.
[11] Carreno L,Lopez-Longo FJ,Gonzalez CM,et al.Treatment options for iuvenile-onset systemic lupus erythematosus.Paediatr Drugs,2002,4(4):241-256.
[12] Mavrikakis I,Sfikakis PP,Mavrikakis E,et al.The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine:a reappraisal.Ophthalmology,2003,110(7):1321-1326.
[13] Fessler BJ,Alarcon GS,McGwin G Jr,et al.Systemic lupus erythematosus in three ethnic groups:XVI.Association of hydroxychloroquine use with reduced risk of damage accrual.Arthritis Rheum,2005,52(5):1473-1480.
[14] Illei GG,Austin HA,Crane M,et al.Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.Ann Intern Med,2001,135(4):248-257.
[15] Filler G,Hansen M,LeBlanc C,et al.Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children.Pediatr Nephrol,2003,18(5):445-449.
[16] Chen TM,Tse KC,Tang CS,et al.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.J Am Soc Nephrol,2005,16(4):1076-1084.
[17] Yoshidome K,Takei S,Imenaka H,et al.Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children.Pediatr Int,2004,46(4):444-449.
[18] Tanaka H,PeTsugawa K,Suzuki K,et al.Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.Pediatr Nephrol,2006,2l(7):962-966.
[19] Willems M,Haddad E,Niaudet P,et al.Rituximab therapy for childhood-onset systemic lupus erythematosus.J Pediatr,2006,148(5):571-573.
[20] Jensson AF,Wintergerst U,Renner ED,et al.Rituximab-induced long-term remission in two children with SLE.Eur J Pediatr,2007,166(2):177-181.
[21] Kamali S,Cefle A,Sayarlioglu M,et al.Experience with monthly,high-dose,intravenous immunoglobulin therapy in patients with difierent connective tissue diseases.Rheumatol Int,2005,25(3):211-214.